A Study of RAY1225 in Participants With Impaired Kidney Function

NCT06613763 | Completed Phase 1

• 1 other identifier: RAY1225-24-06
• Study Type: interventional
• Target: 32
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to assess how fast RAY1225 gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.

Conditions

Kidney Impairment

Outcome Measures

Primary Outcomes (2)

• Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of RAY1225 From Time Zero to T (AUC[0-t])

  Baseline through Day 43

• PK: Maximum Concentration of RAY1225

  Baseline through Day 43

Secondary Outcomes (1)

• Number and severity of participants with Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events(SAE)

  Baseline through Day 43

Study Arms (4)

RAY1225 - Mild Renal Impairment

EXPERIMENTAL

RAY1225 3mg administered SC to participants with mild renal impairment.

Drug: RAY1225

RAY1225 - Moderate Renal Impairment

EXPERIMENTAL

RAY1225 3mg administered SC to participants with moderate renal impairment.

Drug: RAY1225

RAY1225 - Severe Renal Impairment

EXPERIMENTAL

RAY1225 3mg administered SC to participants with severe renal impairment.

Drug: RAY1225

RAY1225 - Control

EXPERIMENTAL

RAY1225 3 milligrams (mg) administered subcutaneously (SC) to healthy participants with normal renal function.

Drug: RAY1225

Interventions

RAY1225 DRUG

Administered SC

RAY1225 - Control; RAY1225 - Mild Renal Impairment; RAY1225 - Moderate Renal Impairment; RAY1225 - Severe Renal Impairment

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Body mass index (BMI) ≥18 to ≤28kg/m2 and total body weight \>50 kg(male) or \>40kg(female) at Screening (calculated as a function of measured height and weight according to the formula, BMI = kg / m2 where m2 is height in meters squared);
• Ability to understand and willingness to sign a written informed consent form;
• Participants with normal renal function only:
• Normal physical examination, vital signs, 12-lead ECG, Chest X-ray images (anteroposterior) and clinical laboratory values, or any abnormality that is non-clinically significant；
• Glomerular filtration rate (GFR)≥ 90 mL/min and \<130 mL/min ；
• Age, BMI, and sex comparable to those of subjects of renal impairment；
• Participants with severe renal impairment only:
• Diagnosis of CKD (any indicators of renal impairment or GFR \< 60 mL/min/1.73 m2 for more than 3 months)；

You may not qualify if:

• Participants with an allergic disposition (multiple drug and food allergies) or who, have known allergies to RAY1225 or related compounds;
• Have a personal or family history of medullary thyroid carcinoma or have multiple endocrine neoplasia syndrome type 2;
• Participants who donated blood or bleeding profusely (\> 400 mL) in the 3 months or donated blood or bleeding profusely (\> 200 mL) in the 1 months;
• Pregnant or lactating women, or women of childbearing age with a positive pregnancy test
• Participants with serious infections, trauma, gastrointestinal surgery or other major surgical procedures within 4 weeks
• Participants with severe renal impairment only:
• Participants with acute renal failure, or a kidney transplant history; or requiring renal dialysis during the study period;
• Hypertension that is not well controlled with antihypertensive medication (systolic blood pressure ≥ 160mm Hg or diastolic blood pressure ≥ 100mm Hg)
• New York heart association (NYHA) class III or IV congestive heart failure
• Alanine aminotransferase (ALT) ≥ 2×ULN, aspartate aminotransferase(AST) ≥ 2×ULN; Serum total bilirubin \> 1.5×ULN;

Sponsors & Collaborators

• Guangdong Raynovent Biotech Co., Ltd: lead

Study Sites (1)

The First Affiliated Hospital of Xiamen University

Xiamen, Fujian, China

Location

MeSH Terms

Conditions

Renal Insufficiency

Condition Hierarchy (Ancestors)

Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 23, 2024
• First Posted: September 26, 2024
• Study Start: September 11, 2024
• Primary Completion: January 10, 2025
• Study Completion: January 20, 2025
• Last Updated: March 5, 2025

Record last verified: 2024-09

Locations

CN (1)